# Patient and Physician Knowledge of Key Safety Messages

> **NCT01907048** · — · COMPLETED · sponsor: **Bayer** · enrollment: 2227 (actual)

## Conditions studied

- Anticoagulation

## Interventions

- **BEHAVIORAL:** Rivaroxaban (Xarelto, BAY59-7939)
- **BEHAVIORAL:** Rivaroxaban (Xarelto, BAY59-7939)

## Key facts

- **NCT ID:** NCT01907048
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09-15
- **Primary completion:** 2020-02-21
- **Final completion:** 2020-04-15
- **Target enrollment:** 2227 (ACTUAL)
- **Last updated:** 2021-04-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01907048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01907048, "Patient and Physician Knowledge of Key Safety Messages". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT01907048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*